MHCD8605

antibody from Invitrogen Antibodies

Targeting: CD86 B7-2, B7.2, CD28LG2

Flow cytometry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MHCD8605

Provider

Invitrogen Antibodies

Product name

CD86 Monoclonal Antibody (BU63), APC

Antibody type

Monoclonal

Antigen

Other

Description

Allophycocyanin (APC) is a stable and highly soluble phycobiliprotein that provides maximal absorbance and fluorescence without susceptibility to internal or external fluorescence quenching, thus providing exceptional quantum yields and molar extinction coefficients.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

BU63

Vial size

500 µL

Storage

4° C, store in dark

References

Submitted references

Recombinant human IL-37 inhibited endometriosis development in a mouse model through increasing Th1/Th2 ratio by inducing the maturation of dendritic cells.

Li L, Liao Z, Ye M, Jiang J
Reproductive biology and endocrinology : RB&E 2021 Aug 24;19(1):128

---

Expression of co-stimulatory molecules CD80 and CD86 is altered in CD14 + HLA-DR + monocytes from patients with Chagas disease following induction by Trypanosoma cruzi recombinant antigens.

Soares AK, Neves PA, Cavalcanti MD, Marinho SM, Oliveira W Júnior, Souza JR, Lorena VM, Gomes YM
Revista da Sociedade Brasileira de Medicina Tropical 2016 Sep-Oct;49(5):632-636

---

Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.

Martin S, Dudek-Perić AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S, Swinnen JV, Agostinis P
Biochemical pharmacology 2015 Feb 1;93(3):290-304

---

Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.

Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P
Cancer research 2015 Apr 15;75(8):1603-14

---

ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.

Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, Agostinis P
Autophagy 2013 Sep;9(9):1292-307

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 7 rhIL-37-induced the increasing of CD40, CD80, CD86, and MHC II in DCs was rescued by activation of STAT3. (A-D) The percentages of CD40-, CD80-, CD86-, and MHC II-positive DCs were determined using flow cytometry. N = 3. ** P < 0.01 compared with Control, and ## P < 0.01 compared with Control + rhIL-37

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Additional file 1: Supplementary figure 1 . Detection of the mature DCs percentage. At 24 hours after the last rhIL-37 administration, the percentages of CD40-, CD80-, CD86-, and MHC II-positive DCs in serum were determined using flow cytometry. N = 3.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Additional file 5: Supplementary figure 5 . Analysis of the maturation of DCs. DCs and EMs-DCs were separated, and were then treated with rhIL-37, and then the percentages of CD40-, CD80-, CD86-, and MHC II-positive DCs were determined using flow cytometry. N = 3.